Health Catalyst (HCAT): Buy, Sell, or Hold Post Q2 Earnings?
Despite a recent 48.7% surge in stock price over six months, analysts recommend caution for Health Catalyst (HCAT) due to declining billings, low gross margins, and long customer acquisition payback periods. The company's fundamentals are considered shaky, making its optically cheap valuation risky. Instead, the article suggests looking for more robust investment opportunities.
Health Catalyst stock falls 2.24 percent as CEO reset unfolds
Health Catalyst stock fell 2.24 percent on September 29, 2026, as the company navigates a CEO transition and operates with a smaller business after divesting Vitalware. Despite the stock drop, the healthcare intelligence company reported Q2 2026 revenue of $70.49 million, exceeding its guidance, and reduced its debt by $160 million. Analysts maintain a "Hold" consensus on the stock, with an average 12-month price target of $2.45.
Health Catalyst, Inc. (HCAT) Latest Stock News & Headlines - Yahoo Finance
This Yahoo Finance page provides the latest news and headlines for Health Catalyst, Inc. (HCAT), including stock performance data, analyst opinions, and company announcements. It summarizes recent articles discussing skepticism about certain software and unprofitable stocks, HCAT's fair value changes, board appointments, and leadership changes. The article also presents HCAT's trailing total returns compared to the S&P 500.
Wells Fargo raises Health Catalyst price target to $1.75
Wells Fargo analyst Stan Berenshteyn has raised the price target for Health Catalyst (NASDAQ: HCAT) to $1.75 from $1, while maintaining an Equal-Weight rating. This adjustment reflects a revised valuation outlook for the healthcare data analytics provider. The article also mentions Health Catalyst's participation in the Truist Securities Healthcare Disruptors & Digital Health Conference, where CEO Ben Albert will discuss AI ROI in Healthcare.
Health Catalyst (HCAT) Stock Fair Value Falls As Analysts Cut Targets On Growth Risks
Analysts have revised Health Catalyst's (HCAT) fair value down from approximately US$2.10 to US$1.83 per share, reflecting increased caution due to growth risks, churn, and divestitures. While some analysts maintain a Neutral stance, others have downgraded the stock to Hold and reduced price targets. This shift highlights concerns about the durability of growth in its health technology offerings and ongoing transformation efforts.
Health Catalyst stock trades near lows as small-cap sentiment weakens
Health Catalyst (HCAT) stock is trading near its lows at around USD 1.79, reflecting weakened small-cap sentiment and investor caution. Despite recent revenue growth, the company continues to report net losses, leading analysts to avoid it due to profitability concerns. Its low valuation of 0.6 times forward price-to-sales highlights market skepticism given its loss-making status and the current challenging environment for unprofitable growth stocks.
Simeon Kohl Bought 118% More Shares In Health Catalyst
Health Catalyst CEO Simeon Kohl recently purchased US$105k worth of company stock, increasing his holdings by 118%. This follows other insider buying activity over the past year, with insiders purchasing more shares than they sold, at an average price higher than the current market price. While the company has not been profitable in the last twelve months, these insider transactions suggest a positive outlook on the stock, despite relatively low overall insider ownership.
Health Catalyst Strengthens Its Board with the Appointment of Tami Reller
Health Catalyst announced the appointment of Tami Reller to its board of directors, effective October 1, 2026. Reller will serve as audit chair and a member of the compensation committee, bringing extensive experience in finance, technology, and healthcare delivery. This appointment aligns with Health Catalyst's strategic focus on advancing its AI-forward healthcare intelligence, following Simeon Kohl's new role as CEO.
Health Catalyst Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Health Catalyst, Inc. announced the grant of 2,747,385 restricted stock units (RSUs) to Simeon Kohl, their newly appointed Chief Executive Officer and President, effective September 14, 2026. These inducement awards are part of the Company's 2026 Employment Inducement Incentive Plan, in accordance with Nasdaq Listing Rule 5635(c)(4). A portion of the RSUs will vest in September 2027, with the remainder vesting quarterly thereafter, contingent on Mr. Kohl's continued employment.
Health Catalyst Appoints Simeon Kohl As CEO And President
Health Catalyst has appointed Simeon Kohl as its new CEO and President, effective September 14, 2026. Kohl, who has over 20 years of healthcare experience and previously led Performant Healthcare, will succeed Ben Albert. Albert will transition to Chief Business Officer, focusing on strategic priorities alongside Kohl, who is expected to enhance growth and operational performance for the AI-forward healthcare intelligence company.
Health Catalyst appoints Tami Reller to board a...
Health Catalyst has appointed Tami Reller to its board of directors, effective October 1, 2026, where she will serve as audit chair and join the compensation committee. This strategic move aims to support the company's next phase of growth, focusing on AI-driven healthcare intelligence under new CEO Simeon Kohl. Reller's extensive experience in healthcare and technology, including her past roles at Microsoft and UnitedHealth Group, is expected to help Health Catalyst deliver impactful technology solutions.
Health Catalyst Grants 2.7 Million RSUs to New CEO Simeon Kohl and Discloses Open Market Share Purchases
Health Catalyst (HCAT) granted 2.7 million Restricted Stock Units (RSUs) to its new CEO, Simeon Kohl, as part of his employment agreement, effective September 14, 2026. This RSU grant is under the company's 2026 Employment Inducement Incentive Plan, with a portion vesting on September 14, 2027, and the remainder in quarterly installments. Additionally, Kohl demonstrated confidence in the company by purchasing 59,000 shares of Health Catalyst common stock on the open market.
Health Catalyst Strengthens Its Board with the Appointment of Tami Reller
Health Catalyst, Inc. announced the appointment of Tami Reller to its board of directors, effective October 1, 2026. Reller will serve as audit chair and a member of the compensation committee, bringing extensive experience in healthcare and technology, particularly in finance, growth, operations, marketing, and consumer experience. Her appointment comes as the company continues to advance its AI-forward healthcare intelligence strategy under new leadership.
The Escalator: Inizio, Health Catalyst, Eversana and more
This article, "The Escalator," details recent significant personnel changes across the pharmaceutical, biotech, and medical marketing sectors. It covers new hires, executive promotions, board appointments, and notable departures at various companies including Inizio, Eversana, Health Catalyst, and Flare Therapeutics. The piece highlights the dynamic movement of leadership within the healthcare industry.
Health Catalyst appoints new CEO
Health Catalyst has appointed Simeon Kohl as its new CEO, making him the company's third chief executive this year. Kohl, who previously led Performant Healthcare, will take over on September 14, succeeding Ben Albert. The appointment comes as Health Catalyst focuses on artificial intelligence and navigates revenue declines, including a 13% drop in the second quarter after selling its Vitalware revenue cycle unit.
Mandatory tax sale by Health Catalyst (HCAT) CEO
Health Catalyst (HCAT) CEO Albert Benjamin sold 35,244 shares of common stock on September 10, 2026, for $1.6747 per share. This was a mandatory "sell-to-cover" transaction to satisfy tax withholding obligations related to the vesting of Restricted Stock Units, not a discretionary trade. Following the sale, Benjamin directly holds 1,388,406 shares of common stock.
Investor group asks for clearer plan at Health Catalyst (NASDAQ: HCAT)
Palogic-affiliated investors, holding a 7.1% stake in Health Catalyst (HCAT), have submitted an amended Schedule 13D filing urging the company's board to provide a clearer forward-looking business plan. The group, which acquired its shares for approximately $11.79 million, is requesting more detailed disclosure on R&D costs, enhanced revenue metrics, capital allocation strategies, and a defined path to profitable growth following the VitalWare sale. They emphasized their concerns in a letter sent to Health Catalyst's board on September 4, 2026.
Health Catalyst Appoints Simeon Kohl as Chief Executive Officer and President
Health Catalyst, Inc. has announced the appointment of Simeon Kohl as its new Chief Executive Officer and President, effective September 14, 2026. Kohl, previously CEO of Performant Healthcare, brings over 20 years of experience in healthcare leadership. Current CEO Ben Albert will transition to Chief Business Officer, a strategic move aimed at enhancing the company's growth and operational performance, particularly in AI-forward healthcare intelligence.
Health Catalyst appoints Simeon Kohl as new CEO
Health Catalyst (HCAT) has appointed Simeon Kohl as its new CEO and president, effective September 14, 2026, replacing Ben Albert, who will transition to chief business officer. Kohl brings extensive experience in healthcare technology, having previously led Performant Healthcare through a successful transformation and sale. The company also adopted a new inducement equity plan to support recruitment and M&A, reinforcing its strategic focus on AI-driven growth and a strengthened balance sheet.
Health Catalyst names Simeon Kohl as new CEO By Investing.com
Health Catalyst Inc. has appointed Simeon Kohl as its new Chief Executive Officer, President, and a member of its Board of Directors, effective September 14. Kohl, who previously led Performant Healthcare through a significant transformation, brings over 20 years of experience in the healthcare sector. Current CEO Ben Albert will transition to Chief Business Officer, continuing to contribute to the company's strategic priorities.
Health Catalyst names Simeon Kohl as new CEO By Investing.com
Health Catalyst Inc. announced the appointment of Simeon Kohl as its new Chief Executive Officer, President, and Board member, effective September 14. Kohl, previously CEO of Performant Healthcare, brings over 20 years of healthcare experience. Current CEO Ben Albert will transition to Chief Business Officer, continuing to work with Kohl on strategic priorities.
Health Catalyst (HCAT) CEO offloads 321 shares to cover taxes
Health Catalyst (HCAT) CEO Albert Benjamin sold 321 shares of common stock at $1.7036 per share on September 1, 2026. This transaction was not discretionary but was mandated to cover tax withholding obligations from the vesting of Restricted Stock Units. Following this sale, Benjamin directly holds 1,423,650 shares of Health Catalyst common stock.
Health Catalyst names Simeon Kohl as new CEO
Health Catalyst Inc. has appointed Simeon Kohl as its new Chief Executive Officer, President, and a board member, effective September 14. Kohl previously led Performant Healthcare through a strategic transformation and sale. Current CEO Ben Albert will transition to Chief Business Officer, continuing to work with Kohl on strategic priorities.
Health Catalyst Grants Insider Julie Larson-Green 9,766 Shares at No Cost (NASDAQ: HCAT)
Health Catalyst (NASDAQ: HCAT) has granted insider Julie Larson-Green 9,766 shares at no cost, increasing her total holdings to 185,101 shares. The transaction, classified under SEC code A, took place on September 1, 2026. This action provides insight into changes in insider ownership for investors.
Health Catalyst Shares Fall After Canaccord Genuity Downgrade
Health Catalyst (HCAT) shares fell following a downgrade by Canaccord Genuity from "Buy" to "Hold." The analyst firm also reduced its price target for HCAT to $1.80 from $3.00, contributing to the stock's decline.
HCAT Downgraded by Canaccord Genuity -- Price Target Lowered to $1.80
Health Catalyst (HCAT) has been downgraded by Canaccord Genuity from 'Buy' to 'Hold', with its price target significantly reduced from $3.00 to $1.80. Despite a GuruFocus GF Value™ indicating the stock is 60.3% undervalued at $4.11, the company's low profitability and valuation ranks, coupled with mixed institutional investor sentiment and no recent insider activity, suggest caution for potential investors.
Health Catalyst, GitLab, Elastic, and Marqeta Shares Plummet, What You Need To Know
Shares of Health Catalyst, GitLab, Elastic, and Marqeta experienced significant drops after a Bloomberg report indicated Anthropic's Q2 revenue exceeded $11.5 billion, suggesting AI tools are gaining traction and potentially impacting software companies. This market reaction intensified existing pressure on software stocks, raising concerns about customers shifting budgets to AI assistants. Health Catalyst, in particular, saw a 7% decline, adding to its previous drop due to a weak Q3 revenue forecast and lowered full-year guidance.
Health Catalyst (HCAT) group led by Clint Coghill reports 9.6% ownership stake
A group of investment entities associated with Clint D. Coghill has reported a 9.6% ownership stake in Health Catalyst (HCAT) as of June 30, 2026. This includes direct holdings by Stoney Lonesome HF LP and Drake Helix Holdings, LLC. Clint D. Coghill and CDC Financial, Inc. are deemed to beneficially own a total of 7,095,498 shares, representing this 9.6% of outstanding shares.
Health Catalyst Q2 Earnings Call Highlights
Health Catalyst (NASDAQ: HCAT) reported strong Q2 2026 results, with revenue exceeding guidance and adjusted EBITDA at the high end of expectations. The company strategically divested Vitalware and Med-Metrix for $147 million, using the proceeds to repay approximately $160 million in debt, making the company debt-free on a pro forma basis. Despite lowering its full-year 2026 outlook due to the divestiture and ongoing investments in technology, Health Catalyst is focusing on its core technology opportunities and expects to navigate migration-related churn and services pressures.
HCAT Maintains by Wells Fargo -- Price Target Lowered to $1.50
Wells Fargo has maintained an Equal-Weight rating for Health Catalyst (HCAT) but lowered its price target to $1.50 from $1.75, citing concerns over growth expectations in a challenging healthcare environment. Despite this, GuruFocus assesses HCAT as 57.3% undervalued with a GF Value™ of $4.16 against a current price of $1.77, though its GF Score™ of 52/100 points to challenges in profitability and financial strength. Investors are advised to proceed with caution due to ongoing losses and cash flow issues, despite the perceived undervaluation.
Wells Fargo & Company Has Lowered Expectations for Health Catalyst (NASDAQ:HCAT) Stock Price
Wells Fargo & Company has reduced its price target for Health Catalyst (NASDAQ:HCAT) from $1.75 to $1.50, while maintaining an "equal weight" rating, suggesting a potential 15.49% downside. Despite recent quarterly earnings beating expectations with $0.04 EPS and $70.49 million in revenue, analyst sentiment remains cautious, resulting in an overall "Hold" consensus for the stock. The company continues to face a negative net margin and institutional investors hold a significant portion of its stock.
5 Must-Read Analyst Questions From Health Catalyst’s Q2 Earnings Call
Health Catalyst (HCAT) reported a notable decline in Q2 sales, attributed to client migrations and divestiture of its Vitalware business. While revenue slightly beat analyst estimates, the company lowered its full-year guidance and faces ongoing structural challenges in health systems. Analysts pressed management on future divestitures and the drivers behind the guidance reduction.
Health Catalyst sells VitalWare for $147Mn
Health Catalyst sold its VitalWare subsidiary to Med-Metrix for $147 million in cash, completed on July 31, 2026. This divestiture allowed Health Catalyst to eliminate its credit facility and focus entirely on healthcare intelligence, analytics, and AI. VitalWare, which provides mid-revenue cycle management solutions, generated $37 million in revenue in fiscal year 2025 and enhances Med-Metrix's software offerings.
Health Catalyst, Inc. (NASDAQ:HCAT) Receives Consensus Rating of "Hold" from Analysts
Health Catalyst, Inc. (NASDAQ:HCAT) has received a consensus "Hold" rating from thirteen analysts, with an average 12-month price target of $2.95. The company recently reported better-than-expected quarterly EPS of $0.04 and revenue of $70.49 million, though it remains unprofitable with a negative net margin. Institutional investors hold approximately 85% of the stock.
HCAT Maintained by Citigroup -- Price Target Lowered to $2.00
Citigroup has maintained a neutral rating for Health Catalyst (HCAT) but lowered its price target from $2.50 to $2.00. Despite the stock being potentially undervalued by 58.8% according to GuruFocus's GF Value, concerns remain about the company's profitability and valuation. Investors are advised to exercise caution due to ongoing financial struggles, even though gurus show cautious optimism.
Health Catalyst (NASDAQ:HCAT) Price Target Cut to $2.00 by Analysts at Citigroup
Citigroup has reduced its price target for Health Catalyst (NASDAQ:HCAT) from $2.50 to $2.00, while maintaining a "neutral" rating, indicating a potential 12% upside from its previous close. Despite beating quarterly EPS and revenue estimates, the company continues to report substantial losses, and analysts forecast a full-year loss. The consensus among analysts is a "Hold" rating with an average price target of $2.95, reflecting mixed but cautious sentiment.
Health Catalyst (NASDAQ:HCAT) Issues Quarterly Earnings Results, Beats Estimates By $0.01 EPS
Health Catalyst (NASDAQ:HCAT) reported stronger-than-expected Q2 earnings, with an adjusted EPS of $0.04 and revenue of $70.49 million, surpassing analyst estimates. Despite the beat, the company cut its Q3 and full-year 2026 revenue guidance due to anticipated migration-related churn and costs, leading to a significant 25% drop in stock price. Health Catalyst also completed the divestiture of Vitalware and Med-Metrix for $147 million, using the proceeds to become debt-free.
Health Catalyst (HCAT) Stock Price Sinks On Margin Reset Fears
Health Catalyst (HCAT) saw its stock price drop by 25% following its Q2 2026 report, despite headline numbers not indicating a collapse. The decline is attributed to investor concerns over a changing margin profile due to the sale of the Vitalware unit, the transition to the Ignite platform, and new guidance. The company's Q2 revenue was US$70.5 million, with an adjusted EBITDA of US$9.9 million, but expectations for full-year adjusted gross margin below 50% and a sharp revenue step-down in Q3 have fueled bearish sentiment.
Health Catalyst, Inc. Q2 2026 Earnings Call Summary
Health Catalyst, Inc. recently held its Q2 2026 earnings call, detailing a strategic pivot following the divestiture of its Vitalware business for $147 million. This move allowed the company to repay $160 million in debt and focus on core technology, particularly its 'Project Nexus' strategy. Management anticipates continued revenue headwinds from platform migrations but remains committed to disciplined spending and investments in AI-driven automation and the Ignite interoperability platform.
Why Health Catalyst (HCAT) Shares Are Trading Lower Today
Health Catalyst (HCAT) shares fell 23.1% after the company issued a weak third-quarter revenue forecast and lowered its full-year outlook, despite exceeding second-quarter revenue expectations. The reduced guidance overshadowed the company's Q2 performance and indicates significant challenges ahead. This significant drop follows a recent gain attributed to easing geopolitical tensions and AI-driven M&A in the software sector.
Health Catalyst Shares Tumble Overnight: What Investors Need to Know
Health Catalyst (HCAT) shares plummeted 24.68% in overnight trading after the company issued lower-than-expected third-quarter revenue guidance, despite exceeding its second-quarter revenue guidance. The healthcare intelligence company reported a 13% year-over-year revenue decline in Q2 but saw adjusted EBITDA increase. Investors reacted negatively to the forward-looking financial outlook.
Compared to Estimates, Health Catalyst (HCAT) Q2 Earnings: A Look at Key Metrics
Health Catalyst (HCAT) reported Q2 2026 revenue of $70.49 million, exceeding the Zacks Consensus Estimate by 2.33%, despite a 12.7% year-over-year decline. The company's EPS of $0.04 surpassed the consensus estimate of $0.02 by 100%. Key metrics like professional services revenue and adjusted gross profits also largely outperformed analyst expectations.
Health Catalyst (Nasdaq: HCAT) sells Vitalware, ends credit facility debt
Health Catalyst (HCAT) has completed the sale of its Vitalware business to Med-Metrix for $147 million, using the proceeds to fully repay its credit facility debt of $159.9 million. This move is expected to eliminate approximately $19 million in annual interest expenses and will allow Health Catalyst to focus on its core healthcare intelligence strategy. The company reported Q2 2026 revenue of $70.5 million, a 13% year-over-year decrease, and a net loss of $40.5 million, which included a $27.0 million goodwill impairment.
Health Catalyst (NASDAQ: HCAT) books $151.6M loss and $147M Vitalware sale
Health Catalyst, Inc. (NASDAQ: HCAT) reported a net loss of $151.6 million for the first half of 2026, primarily due to a $122.5 million goodwill impairment charge. The company also announced the sale of its Vitalware business to Med-Metrix for $147 million, with the proceeds used to repay outstanding debt. Revenue declined year-over-year, impacting profitability, though operating cash flow improved.
Health Catalyst, Inc. 2026: Revenue $70.49M, EPS ($0.55) — 10-Q Summary
Health Catalyst, Inc. (HCAT) reported Q3 2026 revenue of $70.49 million, a decline from $80.72 million in the prior year, and a net loss of ($0.55) per diluted share. The company attributes the revenue drop to customer churn from DOS-to-Ignite migrations and the exit of lower-margin arrangements. HCAT is implementing "Project Nexus" to improve operational efficiency and anticipates migration-related churn to conclude by the end of 2027.
Press Release: Health Catalyst Completes Sale of Vitalware, Sharpening Its Focus as a Healthcare Intelligence Company
Health Catalyst has announced the completion of the sale of its Vitalware business to RLDatix. This strategic move allows Health Catalyst to sharpen its focus on its core healthcare intelligence and analytics offerings, streamlining its operations and strengthening its balance sheet. The company anticipates using the proceeds from the sale for general corporate purposes, including potential investments in growth initiatives and debt reduction.
Earnings call transcript: Health Catalyst posts Q2 2026 revenue beat, shares sink
Health Catalyst (HCAT) reported Q2 2026 revenue above Wall Street expectations, reaching $70.5 million, and adjusted EBITDA at the high end of guidance. However, the company's shares sank by over 27% in after-hours trading due to a weaker full-year outlook, which was primarily impacted by the divestiture of Vitalware and ongoing platform migration costs. Management emphasized a strategic shift towards core technology opportunities, debt elimination, and a multi-year transformation, prioritizing long-term value over short-term results.
M&A: Health Catalyst Closes $147M Sale of Vitalware to Med-Metrix
Health Catalyst, a healthcare intelligence company, has completed the sale of its mid-revenue cycle business, Vitalware, to Med-Metrix for $147 million. This divestiture allows Health Catalyst to repay its credit facility, eliminating approximately $19 million in annual interest expense, and focus its capital and operational efforts on scaling its core healthcare intelligence platform and AI-driven decisioning tools. The company aims to leverage its 18 years of proprietary analytics and $2.8 billion in documented clinical and financial outcomes to drive sustainable operational change for health systems.
HEALTH CATALYST ($HCAT) Releases Q2 2026 Earnings
HEALTH CATALYST ($HCAT) announced its Q2 2026 earnings, reporting $0.04 per share, beating estimates by $0.01, and revenue of $70.49 million, surpassing estimates. Despite strong earnings, the stock price decreased by 27.83% since market close. The article also details recent hedge fund activity in HCAT stock and analyst price targets.
Health Catalyst Completes Sale of Vitalware, Sharpening Its Focus as a Healthcare Intelligence Company
Health Catalyst announced the completion of the sale of its Vitalware business to Med-Metrix, LLC, on July 31, 2026, for $147 million. The company used the proceeds to repay its credit facility debt, eliminating approximately $19 million in annual interest expense. This divestiture allows Health Catalyst to sharpen its focus on its core healthcare intelligence strategy, leveraging its 18 years of proprietary data and AI-driven products to help health systems improve performance across cost, clinical quality, and consumer loyalty.
